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TABLE 1. Time trends in number of patients receiving only young or old fresh-frozen plasma
Year Only young FFP* Mixed FFP Only old FFP* Total
2004 2 (2.7%) 1 (1.4%) 71 (96%) 74
2005 0 (0%) 4 (1.1%) 365 (99%) 369
2006 5 (1.2%) 20 (4.8%) 390 (94%) 415
2007 120 (27%) 88 (20%) 243 (54%) 451
2008 283 (57%) 121 (25%) 89 (18%) 493
2009 28 (18%) 25 (16%) 103 (66%) 156
FFP, Fresh-frozen plasma. *Only young and only old defined according to van Straten and colleagues1 at a cutoff of
323 days. Figures represent number of patients and percentages (in parentheses) of the total number of FFP recip-
ients in that year.
Letters to the EditorReply to the Editor:
My colleagues and I appreciate the
comments by Lin and colleagues
regarding potential issues that may
influence outcomes in pexelizumab-
treated patients. Their hypothesis
that pexelizumab may cause platelet
aggregation, however, is not sup-
ported by the literature. We note
that their reference 3 (Røger and col-
leagues) actually suggested that in-
hibiting the terminal complement
cascade with a molecule such as pex-
elizumab might inhibit platelet ag-
gregation. The suggestion of Lin
and colleagues that this compound’s
cardioprotective effect may depend
on the presence of adequate antith-
rombotic therapy is an interesting
but unproven hypothesis. Unfortu-
nately, Lin and colleagues’ sugges-
tion that large amounts of heparin
may achieve longer activated clotting
times to suppress thrombin activity is
also not supported by the literature.1
We also disagree that as time passes,
heparin-bonded circuits may replace
the traditional bypass circuits, be-
cause the literature is equivocal that
reducing perioperative heparin im-
proves safety in cardiac surgical pa-
tients. In fact, there is literature
suggesting that providing even more
systemic heparin might be important
in producing less bleeding in cardiac
surgical patients.2,3
Lin and colleagues is suggested that
we reanalyze the Pexelizumab for Re-
duction of Infarction and Mortality in
Coronary Artery Bypass Graft Sur-
gery data with regard to the use of
heparin-bonded perfusion circuits,
presumably as a surrogate for total
heparin dose, to test their hypothesis.
We have reviewed the data from the
Pexelizumab for Reduction of Infarc-
tion and Mortality in Coronary Artery
Bypass Graft Surgery II trial, in which
27% of the patients were operated on
with heparin-bonded circuits. The pri-
mary end point did not differ between
pexelizumab and placebo groups (rel-
ative risk, 1.02; P ¼ .9319). HeparinThe Journaldosing was not captured in the case re-
port forms.
Peter K. Smith, MD
Department of Surgery
Duke University Medical Center
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doi:10.1016/j.jtcvs.2011.04.008COMMENT ON ‘‘EFFECT OF
STORAGE TIME OF
TRANSFUSED PLASMA ON
EARLYAND LATE MORTALITY
AFTER CORONARYARTERY
BYPASS GRAFTING’’
To the Editor:
Plasma from blood donors is frozen
and stored at30C for a maximum of
2 years. van Straten and colleagues1
recently reported a 3 times increased
30-day mortality after coronary artery
bypass grafting if patients received
fresh-frozen plasma (FFP) that had
been stored for more than 323 days
(old) compared with FFP that hadof Thoracic and Cardiovascular Surgebeen stored for a shorter time (young).
If longer storage of FFP is truly inde-
pendently associated with a higher
mortality, we would need to consider
changing the regulations on storage
times of FFP. However, before jump-
ing to this conclusion, one needs to
carefully consider alternative explana-
tions for the observed association, such
as potential biases and confounding.
The design of the study, a cohort
among consecutive patients undergo-
ing coronary artery bypass grafting in
a period of 10 years, was well chosen,
because the choice to transfuse old or
young FFP is random. Patients who
have received old FFP and patients
who have received young FFP can
therefore be compared as if from a ran-
domized trial. Table 1 in the report can
be used to check whether the random-
ization was successful. Unfortunately,
there are several remarkable differ-
ences between the intervention
groups, such as the number of patients
who underwent reexploration (young
FFP 36% vs old FFP 25%) and plate-
let transfusion (young FFP 0.29 units
vs old FFP 0.42 units). Therefore, we
conclude that proper randomization
was not achieved.
There are several possible explana-
tions for unequal distribution of prog-
nostic factors across the intervention
groups. Changes in techniques to pro-
duce and store FFP, such as leucode-
pletion since 2001 and the male-only
plasma measure since 2007, have all
affected the storage times of FFP dur-
ing the 10-year period of the study.
Therefore, although the choice tory c Volume 142, Number 2 473
